CHMP backs Cyramza, Trulicity and Moventig

EMA's CHMP recommended approval of three compounds already approved in the U.S.: Cyramza ramucirumab and Trulicity dulaglutide from Eli Lilly and Co. (NYSE:LLY), and Moventig naloxegol from AstraZeneca plc (LSE:AZN; NYSE:AZN).

FDA approved Trulicity, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, earlier this month to improve glycemic control in patients with Type II diabetes. ...